Figure 5 displays a forest plot for the network meta-analysis of studies reporting ACR50 response rates. Two comparisons were used in this analysis. Study-level data used in this Figure are presented in Appendix C. This figure is described further in the KQ1 Results section “TNF Biologic: MTX Plus TNF Biologic vs. Monotherapy With Either MTX or TNF Biologic” as follows: “Results of the NWMA were consistent with the findings of the PREMIER study and favored the combination of MTX plus ADA versus ADA monotherapy for higher ACR50 response (relative risk [RR], 1.52; 95% confidence interval [CI], 1.28 to 1.80). NWMA also favored the combination of MTX plus ETN versus ETN for higher ACR50 response (RR, 1.57; 95% CI, 1.23 to 2.02)”.

Figure 5Forest plot for network meta-analysis of ACR50 response rates: MTX plus TNF biologic versus TNF biologic

95% CI = 95% confidence interval; ACR50 = American College of Rheumatology 50% improvement; MTX = methotrexate; RR = relative risk; TNF = tumor necrosis factor; vs. = versus.

From: Results

Cover of Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update
Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update [Internet].
Comparative Effectiveness Review, No. 211.
Donahue KE, Gartlehner G, Schulman ER, et al.
Copyright Notice

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.